Business ❯ Pharmaceutical Industry

Market Analysis

Sales Projections Drug Sales Sales Forecasts Sales Forecast Drug Development Revenue Projections Stock Performance Investor Relations Investor Reactions Competitor Analysis

FDA Approves AstraZeneca’s Baxfendy for Hard-to-Control Hypertension

The oral aldosterone‑blocking pill showed near double‑digit drops in systolic pressure in late‑stage testing.

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Medicus Pharma Reports Long-Acting Hormone Control in Phase 1 Teverelix Data

Insmed Halts Brensocatib in Hidradenitis Suppurativa After Phase 2b Trial Fails

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

BullFrog AI Strikes Top-5 Pharma Deal To Find Depression Drug Targets

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

Bayer’s Asundexian Cuts Recurrent Stroke by 26% in Phase III Without Added Major Bleeding

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

German Insurer TK Sees Up to €11 Billion Annual Savings From Drug Pricing Reforms

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

Orexin-2 Agonists Lift Wakefulness in Narcolepsy as Takeda Leads With Late-Stage Wins

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

UK Grants First Global Approval for GSK’s Blenrep in Two Combination Therapies